Flow cytometry with anti HLA-antibodies: a simple but highly sensitive method for monitoring chimerism and minimal residual disease after HLA-mismatched stem cell transplantation

被引:34
作者
Schumm, M. [1 ]
Feuchtinger, T.
Pfeiffer, M.
Hoelle, W.
Bethge, W.
Ebinger, M.
Kuci, S.
Handgretinger, R.
Lang, P.
机构
[1] Univ Childrens Hosp, Dept Pediat Oncol, Hoppe Seyler St 1, D-72076 Tubingen, Germany
[2] Univ Tubingen Hosp, Dept Internal Med, Tubingen, Germany
关键词
chimerism; haploidentical; ow cytometry; transplantation; HLA;
D O I
10.1038/sj.bmt.1705676
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Transplantation of HLA-mismatched stem cells may allow determination of chimerism status of single cells by differential expression of HLA molecules. Monoclonal antibodies against HLA antigens can be used to determine the HLA type of sub-populations by standard flow cytometry. Blood samples from 23 patients transplanted from HLA-mismatched family donors were monitored using HLA-specific antibodies. Suitable antibodies could be found for all donor recipient pairs by using differences in HLA Bw4 and Bw6 groups or other serological antigens. Pretransplant controls of donor and recipient were used to correct for variable fluorescence intensities of the antibodies and sub-populations. Owing to the high sensitivity, cell populations with a minimum frequency of 0.1% were detectable. Flow-cytometric analysis was confirmed by chimerism analysis of immunomagnetically isolated T cells by standard PCR technique. In addition to chimerism evaluation, HLA antibodies improved the detection of leukemic cells after transplantation with aberrant phenotype. In conclusion, flow cytometry using antibodies against HLA antigens is an interesting tool for determination of chimerism and minimal residual disease after HLA-mismatched transplantation. Information about the chimerism status is given on a single-cell level and allows fast and convenient analysis of sub-populations.
引用
收藏
页码:767 / 773
页数:7
相关论文
共 32 条
  • [1] Induction of donor-type chimerism and transplantation tolerance across major histocompatibility barriers in sublethally irradiated mice by Sca-1+Lin- bone marrow progenitor cells:: Synergism with non-alloreactive (Host x Donor)F1 T cells
    Bachar-Lustig, E
    Li, HW
    Gur, H
    Krauthgamer, R
    Marcus, H
    Reisner, Y
    [J]. BLOOD, 1999, 94 (09) : 3212 - 3221
  • [2] Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL
    Bader, P
    Hancock, J
    Kreyenberg, H
    Goulden, NJ
    Niethammer, D
    Oakhill, A
    Steward, CG
    Handgretinger, R
    Beck, JF
    Klingebiel, T
    [J]. LEUKEMIA, 2002, 16 (09) : 1668 - 1672
  • [3] Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy
    Bader, P
    Niemeyer, C
    Willasch, A
    Kreyenberg, H
    Strahm, B
    Kremens, B
    Gruhn, B
    Dilloo, D
    Vormoor, J
    Lang, P
    Niethammer, D
    Klingebiel, T
    Beck, JF
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (05) : 649 - 658
  • [4] Bader P, 1996, ANTICANCER RES, V16, P1759
  • [5] Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: Fast engraftment and low toxicity
    Bethge, Wolfgang A.
    Haegele, Matthias
    Faul, Christoph
    Lang, Peter
    Schumm, Michael
    Bornhauser, Martin
    Handgretinger, Rupert
    Kanz, Lothar
    [J]. EXPERIMENTAL HEMATOLOGY, 2006, 34 (12) : 1746 - 1752
  • [6] Campana D, 1999, CYTOMETRY, V38, P139, DOI 10.1002/(SICI)1097-0320(19990815)38:4<139::AID-CYTO1>3.0.CO
  • [7] 2-H
  • [8] CEREDIG R, 1984, THYMUS, V6, P15
  • [9] Cotteret S, 1998, CYTOMETRY, V34, P216, DOI 10.1002/(SICI)1097-0320(19981015)34:5<216::AID-CYTO2>3.3.CO
  • [10] 2-5